The Cleerly-initiated Medicare coverage will begin covering AI-QCT on November 24, 2024
Medicare Administrative Contractors Approve Coverage of Cleerly Heart Scans to Medicare Recipients
Cleerly Media Contact
Christy Sievert
press@cleerlyhealth.com
Several Medicare Administrative Contractors (MACs) have officially approved Artificial Intelligence-enabled Quantitative Coronary Topography (AI-QCT) scans for Medicare recipients with stable and acute symptoms suspicious of coronary artery disease. Cleerly, the company on a mission to eradicate heart attacks, requested the decision on MAC coverage in February of 2023 to expand coverage of potentially life-saving AI technology to Medicare recipients at risk for future heart attacks.
This coverage will go into full effect November 24, 2024 in the Palmetto GBA, CGS Administrators, National Government Services (NGS), and WPS administrative groups. In the United States, MACs provide coverage for approximately 34 million Medicare beneficiaries.
Cleerly’s AI-QCT technology, Cleerly Labs, provides a comprehensive, standardized and reproducible assessment of coronary artery disease based on a noninvasive Cardiac Computed Tomography Angiography (CCTA). AI-based Cleerly Labs, in several studies comparing it with invasive gold standards, has been demonstrated to be highly accurate in the assessment of the presence, extent, and composition of coronary atherosclerotic plaque and similar to consensus readings of Level 3 Expert Physician Readers. The new Medicare coverage will include Cleerly Labs Plaque Analysis for patients with acute or stable chest pain with no known CAD, and CAD-RADS 1-3.
“We applaud this decision by the MACs to extend coverage for AI-QCT. When we first requested a coverage decision for Cleerly Labs, our goal was to ensure at-risk patients had coverage for the most advanced cardiovascular testing technology that can most effectively guide clinical decision making,” said James K. Min, MD, Founder and CEO of Cleerly. “We are also extremely thankful to the many physicians and medical society partners who used their voices to advocate for this essential AI-QCT technology. Until Cleerly, healthcare providers have not had a way to easily and completely assess the primary cause of heart attacks, atherosclerotic plaque burden and type, in a noninvasive way, which is especially important for our senior population. This decision by the MACs represents a significant step in advancing the field of cardiology, and providing the best possible care for our seniors.”
To request a Cleerly scan, please see Cleerly heart scan locations here or reach out to us here.
About Cleerly®
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014694634/en/
